Sector News

Big price hikes widespread in pharma, with dozens doubling last year: Bloomberg

February 3, 2016
Life sciences

Lately, the spotlight has turned on Valeant and Turing Pharmaceuticals when it comes to the drug-pricing debate. But the price-hiking strategy goes far, far beyond that pair of drugmakers.

A survey of roughly 3,000 brand-name prescription treatments has found that prices more than doubled on 60 of them since December 2014, Bloomberg reports. And they’ve more than quadrupled on 20 of the medications over that same timeframe.

According to the survey, conducted by price-comparison software provider DRX, Mylan’s Aloprim is among the products that saw the biggest jack-ups. The cost for a vial of that drug, which treats cancer complications, increased more than twofold, Bloomberg notes.

“The data shows that price increases are an integral part of the business plan,” Jim Yocum, EVP at DRX, told the news service.

But Mylan is hardly alone. Last October, The Wall Street Journal pointed to a slew of Big Pharma moneymakers that owed part of their success to hefty price increases–including Biogen’s Avonex, Eli Lilly’s Humalog, Novartis’ Gleevec and Pfizer’s Lyrica and Viagra.

And while Valeant has pledged to nix most of its planned price increases this year, recent political pushback and public scrutiny haven’t convinced some of its peers to do away with the practice. As Deutsche Bank analysts pointed out last month, Pfizer boosted the list prices of dozens of therapies for the new year by an average of 10.6%. They also highlighted hikes at Allergan and Endo, where painkiller Percocet jumped up by 25%. Raymond James analysts unveiled an 8% increase in Amgen’s Enbrel, which followed an 8% increase last September and a 10% increase last May. And the list goes on.

As drugmakers have argued, boosting their list prices doesn’t mean necessarily boosting their bottom lines all that much. Insurers and health plans negotiate discounts, meaning pharma companies don’t reap the entire increase. Still, as Yocum pointed out, a higher starting point for negotiations helps them end up at a higher finishing point. “Even if they don’t get all of that price increase, they will get some of it,” he told Bloomberg.

Meanwhile, it’s former Turing CEO Martin Shkreli and interim Valeant CEO Howard Schiller who will land in the congressional hot seat later this week. The two are scheduled to appear before The House Committee on Oversight and Government Reform to explain increases on Turing’s Daraprim and Valeant heart meds Isuprel and Nitropress, whose prices skyrocketed after being acquired by their current owners.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.